Analysis  ||| S:0 E:9 ||| NN
of  ||| S:9 E:12 ||| IN
serum  ||| S:12 E:18 ||| JJ
cytokine  ||| S:18 E:27 ||| JJ
levels  ||| S:27 E:34 ||| NNS
in  ||| S:34 E:37 ||| IN
larynx  ||| S:37 E:44 ||| JJ
squamous  ||| S:44 E:53 ||| JJ
cell  ||| S:53 E:58 ||| NN
carcinoma  ||| S:58 E:68 ||| NNS
and  ||| S:68 E:72 ||| CC
dysplasia  ||| S:72 E:82 ||| JJ
patients  ||| S:82 E:91 ||| NNS
Although  ||| S:91 E:100 ||| IN
the  ||| S:100 E:104 ||| DT
imbalance  ||| S:104 E:114 ||| NN
of  ||| S:114 E:117 ||| IN
cytokines  ||| S:117 E:127 ||| NN
in  ||| S:127 E:130 ||| IN
Head  ||| S:130 E:135 ||| NNP
and  ||| S:135 E:139 ||| CC
Neck  ||| S:139 E:144 ||| NNP
Squamous  ||| S:144 E:153 ||| NNP
Cell  ||| S:153 E:158 ||| NNP
Carcinoma  ||| S:158 E:168 ||| NNP
( ||| S:168 E:169 ||| -LRB-
HNSCC ||| S:169 E:174 ||| NNP
)  ||| S:174 E:176 ||| -RRB-
is  ||| S:176 E:179 ||| VBZ
well  ||| S:179 E:184 ||| RB
known ||| S:184 E:189 ||| VBN
,  ||| S:189 E:191 ||| ,
there  ||| S:191 E:197 ||| EX
is  ||| S:197 E:200 ||| VBZ
scarce  ||| S:200 E:207 ||| JJ
data  ||| S:207 E:212 ||| NNS
regarding  ||| S:212 E:222 ||| VBG
its  ||| S:222 E:226 ||| PRP$
occurrence  ||| S:226 E:237 ||| NN
during  ||| S:237 E:244 ||| IN
dysplasia ||| S:244 E:253 ||| NN
,  ||| S:253 E:255 ||| ,
before  ||| S:255 E:262 ||| IN
the  ||| S:262 E:266 ||| DT
malignant  ||| S:266 E:276 ||| JJ
transformation ||| S:276 E:290 ||| NN
.  ||| S:290 E:292 ||| .
To  ||| S:292 E:295 ||| TO
determine  ||| S:295 E:305 ||| VB
whether  ||| S:305 E:313 ||| IN
laryngeal  ||| S:313 E:323 ||| JJ
dysplasia  ||| S:323 E:333 ||| JJ
patients  ||| S:333 E:342 ||| NNS
show  ||| S:342 E:347 ||| VBP
a  ||| S:347 E:349 ||| DT
different  ||| S:349 E:359 ||| JJ
cytokine  ||| S:359 E:368 ||| JJ
profile  ||| S:368 E:376 ||| NN
than  ||| S:376 E:381 ||| IN
patients  ||| S:381 E:390 ||| NNS
with  ||| S:390 E:395 ||| IN
cancer  ||| S:395 E:402 ||| NN
and  ||| S:402 E:406 ||| CC
healthy  ||| S:406 E:414 ||| JJ
controls ||| S:414 E:422 ||| NNS
.  ||| S:422 E:424 ||| .
Seventeen  ||| S:424 E:434 ||| NNP
newly  ||| S:434 E:440 ||| RB
diagnosed ||| S:440 E:449 ||| VBN
,  ||| S:449 E:451 ||| ,
untreated  ||| S:451 E:461 ||| FW
larynx  ||| S:461 E:468 ||| FW
squamous  ||| S:468 E:477 ||| FW
cell  ||| S:477 E:482 ||| FW
carcinoma  ||| S:482 E:492 ||| FW
( ||| S:492 E:493 ||| -LRB-
SCC ||| S:493 E:496 ||| NNP
)  ||| S:496 E:498 ||| -RRB-
and  ||| S:498 E:502 ||| CC
six  ||| S:502 E:506 ||| CD
laryngeal  ||| S:506 E:516 ||| CD
dysplasia  ||| S:516 E:526 ||| CD
patients  ||| S:526 E:535 ||| NNS
as  ||| S:535 E:538 ||| IN
well  ||| S:538 E:543 ||| RB
as  ||| S:543 E:546 ||| IN
22  ||| S:546 E:549 ||| CD
healthy  ||| S:549 E:557 ||| JJ
controls  ||| S:557 E:566 ||| NNS
were  ||| S:566 E:571 ||| VBD
analyzed  ||| S:571 E:580 ||| VBN
for  ||| S:580 E:584 ||| IN
circulating  ||| S:584 E:596 ||| VBG
cytokines ||| S:596 E:605 ||| NNS
.  ||| S:605 E:607 ||| .
A  ||| S:607 E:609 ||| DT
flowcytometry  ||| S:609 E:623 ||| FW
Th1 ||| S:623 E:626 ||| FW
/ ||| S:626 E:627 ||| FW
Th2  ||| S:627 E:631 ||| FW
cytokine  ||| S:631 E:640 ||| FW
array  ||| S:640 E:646 ||| NN
kit  ||| S:646 E:650 ||| NN
was  ||| S:650 E:654 ||| VBD
used  ||| S:654 E:659 ||| VBN
to  ||| S:659 E:662 ||| TO
quantitatively  ||| S:662 E:677 ||| VB
measure  ||| S:677 E:685 ||| NN
Interleukin-2  ||| S:685 E:699 ||| NNP
( ||| S:699 E:700 ||| -LRB-
IL-2 ||| S:700 E:704 ||| NNP
) ||| S:704 E:705 ||| -RRB-
,  ||| S:705 E:707 ||| ,
IL-4 ||| S:707 E:711 ||| NN
,  ||| S:711 E:713 ||| ,
IL-6 ||| S:713 E:717 ||| NNP
,  ||| S:717 E:719 ||| ,
IL-10 ||| S:719 E:724 ||| NNP
,  ||| S:724 E:726 ||| ,
Tumor  ||| S:726 E:732 ||| NNP
Necrosis  ||| S:732 E:741 ||| NNP
Factor-α  ||| S:741 E:750 ||| NNP
( ||| S:750 E:751 ||| -LRB-
TNF-α ||| S:751 E:756 ||| NNP
)  ||| S:756 E:758 ||| -RRB-
and  ||| S:758 E:762 ||| CC
Interferon-γ  ||| S:762 E:775 ||| NNP
( ||| S:775 E:776 ||| -LRB-
IFN-γ ||| S:776 E:781 ||| NNP
)  ||| S:781 E:783 ||| -RRB-
levels ||| S:783 E:789 ||| NNS
.  ||| S:789 E:791 ||| .
Additionally ||| S:791 E:803 ||| RB
,  ||| S:803 E:805 ||| ,
IL-8  ||| S:805 E:810 ||| CD
levels  ||| S:810 E:817 ||| NNS
were  ||| S:817 E:822 ||| VBD
determined  ||| S:822 E:833 ||| VBN
through  ||| S:833 E:841 ||| IN
ELISA ||| S:841 E:846 ||| NNP
.  ||| S:846 E:848 ||| .
IL-6 ||| S:848 E:852 ||| NNP
,  ||| S:852 E:854 ||| ,
IL-8  ||| S:854 E:859 ||| NNP
and  ||| S:859 E:863 ||| CC
IL-10  ||| S:863 E:869 ||| NNP
were  ||| S:869 E:874 ||| VBD
determined  ||| S:874 E:885 ||| VBN
to  ||| S:885 E:888 ||| TO
be  ||| S:888 E:891 ||| VB
statistically  ||| S:891 E:905 ||| RB
increased  ||| S:905 E:915 ||| VBN
in  ||| S:915 E:918 ||| IN
SCC  ||| S:918 E:922 ||| NNP
patients  ||| S:922 E:931 ||| NNS
( ||| S:931 E:932 ||| -LRB-
p  ||| S:932 E:933 ||| CD
< ||| S:933 E:934 ||| SYM
0.05 ||| S:934 E:938 ||| CD
) ||| S:938 E:939 ||| -RRB-
.  ||| S:939 E:941 ||| .
IL-8  ||| S:941 E:946 ||| NNP
and  ||| S:946 E:950 ||| CC
IL-10  ||| S:950 E:956 ||| CD
levels  ||| S:956 E:963 ||| NNS
were  ||| S:963 E:968 ||| VBD
also  ||| S:968 E:973 ||| RB
higher  ||| S:973 E:980 ||| JJR
in  ||| S:980 E:983 ||| IN
SCC  ||| S:983 E:987 ||| NNP
patients  ||| S:987 E:996 ||| NNS
than  ||| S:996 E:1001 ||| IN
dysplasia  ||| S:1001 E:1011 ||| JJ
patients  ||| S:1011 E:1020 ||| NNS
( ||| S:1020 E:1021 ||| -LRB-
p  ||| S:1021 E:1022 ||| CD
< ||| S:1022 E:1023 ||| SYM
0.05 ||| S:1023 E:1027 ||| CD
) ||| S:1027 E:1028 ||| -RRB-
.  ||| S:1028 E:1030 ||| .
Additionally ||| S:1030 E:1042 ||| RB
,  ||| S:1042 E:1044 ||| ,
IL-6  ||| S:1044 E:1049 ||| NNP
and  ||| S:1049 E:1053 ||| CC
IL-10  ||| S:1053 E:1059 ||| NNP
were  ||| S:1059 E:1064 ||| VBD
all  ||| S:1064 E:1068 ||| DT
found  ||| S:1068 E:1074 ||| VBN
to  ||| S:1074 E:1077 ||| TO
be  ||| S:1077 E:1080 ||| VB
markedly  ||| S:1080 E:1089 ||| RB
increased  ||| S:1089 E:1099 ||| VBN
in  ||| S:1099 E:1102 ||| IN
dysplasia  ||| S:1102 E:1112 ||| JJ
patients  ||| S:1112 E:1121 ||| NNS
compared  ||| S:1121 E:1130 ||| VBN
with  ||| S:1130 E:1135 ||| IN
controls  ||| S:1135 E:1144 ||| NNS
( ||| S:1144 E:1145 ||| -LRB-
p  ||| S:1145 E:1146 ||| CD
< ||| S:1146 E:1147 ||| SYM
0.05 ||| S:1147 E:1151 ||| CD
) ||| S:1151 E:1152 ||| -RRB-
.  ||| S:1152 E:1154 ||| .
Our  ||| S:1154 E:1158 ||| PRP$
results  ||| S:1158 E:1166 ||| NNS
demonstrate  ||| S:1166 E:1178 ||| VBP
an  ||| S:1178 E:1181 ||| DT
imbalance  ||| S:1181 E:1191 ||| NN
of  ||| S:1191 E:1194 ||| IN
IL-6  ||| S:1194 E:1199 ||| NNP
and  ||| S:1199 E:1203 ||| CC
IL-10  ||| S:1203 E:1209 ||| NNP
not  ||| S:1209 E:1213 ||| RB
only  ||| S:1213 E:1218 ||| RB
in  ||| S:1218 E:1221 ||| IN
HNSCC  ||| S:1221 E:1227 ||| NNP
but  ||| S:1227 E:1231 ||| CC
also  ||| S:1231 E:1236 ||| RB
in  ||| S:1236 E:1239 ||| IN
laryngeal  ||| S:1239 E:1249 ||| JJ
dysplasia ||| S:1249 E:1258 ||| NN
.  ||| S:1258 E:1260 ||| .
